Research programme: serine protease inhibitors - Pharis biotec

Drug Profile

Research programme: serine protease inhibitors - Pharis biotec

Alternative Names: LEKTI - Pharis Biotec; Lympho-epithelial Kazal type inhibitor; SPINK5 - Pharis Biotec

Latest Information Update: 25 Jan 2016

Price : $50

At a glance

  • Originator Pharis Biotec
  • Class Peptides
  • Mechanism of Action Serine protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top